Published in final edited form as:

Liver Int. 2015 August ; 35(8): 2060. doi:10.1111/liv.12803.

Response to 'Is AST-to-platelet ratio index a reliable tool in HIV patients in Africa?'

Michael J. Vinikoor^{1,2}, Edford Sinkala^{3,4}, Gilles Wandeler^{5,6}, and Benjamin H. Chi^{2,7}

¹Department of Medicine, University of North Carolina at Chapel Hill, North Carolina, USA

²Centre for Infectious Disease Research in Zambia, Lusaka, Zambia

³Department of Medicine, University of Zambia, Lusaka, Zambia

⁴University Teaching Hospital, Lusaka, Zambia

⁵Institute of Social and Preventive Medicine, University of Bern, Switzerland

⁶Department of Infectious Diseases, University Hospital Bern, Switzerland

⁷Department of Obstetrics and Gynecology, University of North Carolina at Chapel Hill, North Carolina, USA

Keywords

Africa; AST-to-platelet ratio index; FIB-4; hepatitis B virus; HIV/AIDS; liver disease

Although AST-to-platelet ratio index (APRI) and FIB-4 have been compared with liver biopsy in patients with hepatitis C virus (HCV), hepatitis B virus (HBV), HIV/HCV co-infection, and HIV/HBV co-infection, Johannessen and Lemoine stress that they have not been validated in HIV mono-infected populations in SSA. However, this is unlikely to occur because liver biopsy does not play a role in HIV management and the procedure carries its own risks for complication. Clinicians using APRI and FIB-4 in this setting should be aware of this limitation and should interpret test results in the context of each patient's clinical scenario.

While it elevates APRI or FIB-4 scores, HIV-associated thrombocytopenia (HAT) does not fully explain the association of these markers with mortality. In our analysis, an elevated APRI score at start of antiretroviral therapy predicted all-cause mortality — even among patients with WHO clinical stage 1 or 2 and CD4+ counts >200 cells/mm² who were unlikely to have HAT [1]. In a sensitivity analysis not included in the primary manuscript, we replaced each patient's platelet count with the median value of $238 \times 10^9/L$. As expected, the percentage with APRI 1.5 decreased from 5.1% to 1.9%; however, the association with mortality was similar (adjusted hazard ratio 1.62; 95% CI, 1.29-2.05).

Corresponding Author: Dr. Michael J. Vinikoor, University of North Carolina at Chapel Hill, Centre for Infectious Disease Research in Zambia, 5032 Great North Road, P.O. Box 34681, Lusaka, Zambia; mjv@med.unc.edu, Tel: +26 0211242257, Fax: +26 0211242263.

Conflict of interest: All other authors report no conflicts of interest.

In their letter to the editor, Johannessen and Lemoine speculate that the excess mortality experienced by patients with elevated APRI was unlikely a direct result of liver disease. Unfortunately, as is common in Africa, causes of death were not available in our large observational cohort, making this a difficult question to answer. However liver-related mortality was plausible, since HIV itself can interact with and infect multiple liver cell types [2,3] with potential clinical consequences [4] that are not fully understood, and chronic HBV, the leading cause of advanced liver disease in Africa, was not comprehensively screened for in our cohort. Further investigation is needed to better understand the contribution of liver disease to all-cause mortality among patients on HIV treatment.

Finally, it is important to note that APRI and FIB-4 independently predicted ART mortality in our analysis and may thus have a prognostic role in HIV care in SSA. As our colleagues suggest, further research is certainly needed to better define underlying biological mechanisms to determine how to incorporate their use at scale. Given the limited capacity for diagnosis and management of liver disease, however, such non-invasive metrics appear highly promising for future work.

Acknowledgments

Financial support: Research was supported by the Fogarty International Center of the U.S. National Institutes of Health (K01TW009998 and R25TW009340) and by an Ambizione-PROSPER fellowship (PZ00P3_154730) from the Swiss National Science Foundation.

List of abbreviations

APRI	AST-to-platelet ratio
HAT	HIV-associated thrombocytopenia
HIV	human immunodeficiency virus
HBV	hepatitis B virus
HCV	hepatitis C virus

References

- [1]. Vinikoor MJ, Sinkala E, Mweemba A, Zanolini A, Mulenga L, Sikazwe I, et al. Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. *Liver International*. 2015
- [2]. Blackard J, Sherman K. HCV/HIV co-infection: time to re-evaluate the role of HIV in the liver? *Journal of viral hepatitis*. 2008; 15(5):323–330. [PubMed: 18208497]
- [3]. Xiao P, Usami O, Suzuki Y, Ling H, Shimizu N, Hoshino H, et al. Characterization of a CD4-independent clinical HIV-1 that can efficiently infect human hepatocytes through chemokine (CXC motif) receptor 4. *Aids*. 2008; 22(14):1749–1757. [PubMed: 18753859]
- [4]. Kovari H, Ledergerber B, Battegay M, Rauch A, Hirschel B, Foguena AK, et al. Incidence and risk factors for chronic elevation of alanine aminotransferase levels in HIV-infected persons without hepatitis b or c virus co-infection. *Clinical infectious diseases*. 2010; 50(4):502–511. [PubMed: 20085465]